Overview A Study to Evaluate the Efficacy and Safety of AD-208 Status: Recruiting Trial end date: 2022-04-22 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the efficacy and safety of AD-208. Phase: Phase 3 Details Lead Sponsor: Addpharma Inc.